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Introduction
Medicines have made an appreciable contribution to improving 
health outcomes [1,2]. However, pharmaceutical expenditure is coming 
under increasing scrutiny worldwide [3,4] with expenditure rising by 
more than 50% in real terms during the past decade among OECD 
countries [5]. This growth has resulted in pharmaceutical expenditure 
now the largest, or equalling the largest, cost component in ambulatory 
care, and in some countries is up to 60% of total healthcare expenditure 
[4,6]. This scrutiny will continue with ever increasing pressure on 
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Abstract
Introduction: Medicines have made an appreciable contribution to improving patient care in recent years. However, 
European and other countries are increasingly struggling to fund new premium priced medicines. This has resulted in models to 
optimise their utilisation as well as multiple initiatives to improve the prescribing of established medicines including enhancing 
the use of low cost generics, improving adherence to prescribing guidance as well as access to medicines, ensuring adequate 
doses are prescribed and improving patient adherence rates especially in chronic asymptomatic conditions.
Objective: Review a range of demand-side initiatives in ambulatory care across different countries and their resultant 
effects to provide future direction.
Methodology: Principally a narrative review of case histories of published studies.
Results: Measures to encourage the prescribing of low cost generics versus originators and patented products in a class 
can release considerable resources without compromising care. However, there is no ‘spill over’ effect between classes. 
Consequently, multiple demand-side measures are needed to effect changes in physician prescribing habits. In addition, there 
are classes where there is caution, e.g. atypical antipsychotics. Activities surrounding the ‘Wise List’ in Stockholm healthcare 
region, including continuous medical education with resultant high prescribing adherence rates to a list of approximately 
200 medicines, provides guidance to authorities where there are currently limited programmes to improve the quality of 
prescribing. Adequate dosing can be a concern necessitating strategies to assess current dosing levels to plan for the future 
including potential ways to address this. There are also concerns with adherence rates especially among patients with chronic 
asymptomatic diseases. This is resulting in activities by authorities to address this including adherence clinics. 
Discussion: Multiple measures can enhance the quality and efficiency of prescribing, and authorities need to continually 
learn from each other to achieve desired results. The involvement of all key stakeholder groups including patients, pharmacists 
and physicians can enhance the rational use of medicines and enhance prescribing efficiency.
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available resources, caused by well defined factors including ageing 
populations, rising patient expectations and the continued launch of 
new premium priced technologies as single or combined entities [3,7-
9].
European and other countries are increasingly struggling to fund 
new premium priced medicines due to resource issues [10-12]. If not 
addressed, this will grow commensurably with increasing prices of new 
biological drugs, which account for an appreciable number of new 
medicines in development [13]. These are typically priced between 
US$100,000 to US$400,000 (€74,000-296,000) per patient per year or 
more [7,14,15]. In addition, new treatments whilst effective could have 
an appreciable impact on overall drug expenditure as potentially seen 
with new treatments for patients with hepatitis C virus [16]. Measures 
to optimise the use of new medicines include models to improve their 
managed entry, starting pre-launch and continuing post-launch [12,17]. 
Initiatives also include an increase in managed entry agreements to 
enhance the value of new medicines, and hence their potential funding, 
together with the evaluation of data from registries and databases 
post-launch to assess utilisation patterns as well as the effectiveness 
and safety of new medicines in routine clinical care [9,18-25]. These 
activities will continue. However, care is needed with managed entry 
agreements given current concerns with the level of administration, 
apart from potentially straight discounts, the need to engage qualified 
unbiased professionals including physicians when appraising them 
as well as necessary information technology sophistication for any 
proposed outcome-based scheme [12,18,26].
Multiple demand-side reforms and initiatives are also being 
instigated by health authorities, physicians and pharmacists across 
countries to improve the quality and efficiency of prescribing with 
established medicines. These include measures to enhance the use of 
generics versus originators through for instance encouraging voluntary 
International Non-proprietary name (INN) prescribing; alternatively, 
instigating compulsory INN prescribing [10,27,28,30] or compulsory 
generic substitution [31,33]. Alongside this, measures to encourage 
the prescribing of generics versus patented (single-sourced) products 
in a class where all the products in the class are seen as essentially 
therapeutically similar at appropriate doses, e.g. the proton pump 
inhibitors (PPIs), statins and the renin-angiotensin inhibitor drugs, 
which include both the angiotensin converting enzyme inhibitors 
(ACEIs) and angiotensin receptor blockers (ARBs) [29,34-43].
Such multiple demand-side measures can result in appreciable 
savings especially when coupled with low prices of generics, which 
can be as low as 2-10% of pre-patent loss prices in some countries 
[29,32,36,44-46] The savings from increasing the use of generics 
can help fund new medicines, increased drug volumes, increased 
patient access or a mixture of these. This is important given the 
continual pressure on resources coupled with annual global sales of 
pharmaceutical products losing their patents between 2008 and 2013 
estimated at US$50 to 100 billion (€35-70 billion). This rises to US$255 
billion (€190 billion) between 2011 and 2016 [47-49].
Other potential measures to improve the quality and efficiency 
of prescribing include initiatives to enhance physician involvement 
in continuous medical education programmes including educational 
initiatives around a selected list of well proven medicines, which are 
typically available as generics [32,50]. Patient care is enhanced through 
increased physician familiarity with the medicines they prescribe 
[50,51], potentially reducing adverse drug reactions (ADRs) as well as 
drug interactions. Average treatment costs for a single ADR in Germany 
were estimated at approximately €2250, equating to €434million per 
year [52], with the cost of emergency related admissions in the UK 
due to ADRs estimated at GB£2billion (€2.4billion) annually [53]. In 
the US, the cost of drug-related morbidity and mortality exceeded 
US$177billion (€130billion) alone in 2000 [54]. Pharmacists working 
with medicine management teams within health authorities can also 
play a role to improve care through academic detailing activities, 
working in pharmacotherapeutic teams including quality circles as 
well as part of therapeutic switching programmes in agreed patient 
populations [36,45,55-58].
Prescribing adequate doses and routinely monitoring patient 
outcomes is the basis of effective and safe drug therapy [50,51,59]. 
Published studies have shown that regular monitoring of International 
Normalisation Ratio (INR) levels with warfarin is variable across 
countries[60], which needs to be addressed. Published studies have 
also shown that good control of blood pressure in patients with 
hypertension and type 2 diabetes is essential to achieve a clinically 
important reduction in the risk of death and complications related 
to diabetes, including progression of diabetic retinopathy and 
deterioration in visual acuity [61]. However, regular monitoring of 
blood pressure is variable across countries. The same is also true with 
the prescribing of statins in patients with coronary vascular disease, 
with published studies showing substantial variation in the dosing of 
simvastatin for secondary prevention despite guidelines advocating 40 
mg simvastatin [27,38,39]. Perreault and colleagues showed that good 
adherence to statins in patients with primary prevention was associated 
with a risk reduction of 18% compared with <20% for the remainder 
[62]. However, adherence can be low in patients with asymptomatic 
chronic diseases [63,64], e.g. Cramer and colleagues found that only 
59% of patients took their medication for the treatment of diabetes, 
hypertension and dyslipidaemia for more than 80% of their days 
‘on therapy’ in a year [65]. Medication adherence refers to the act 
of continuing the treatment for the prescribed duration, which is 
different to compliance as this typically refers to the degree or extent 
of conformity to the recommendations about day-to-day treatment 
with respect to the timing, dosage, and frequency [66]. Findings such 
as these resulted in blood pressure and lipid level targets in patients 
with diabetes, hypertension and cardiovascular disease included in UK 
quality standards (QoF) [28,29,44,67,68]. In addition, introduction of 
medication adherence clinics by health authorities, e.g. Malaysia [69]. 
These issues need to be addressed to improve morbidity and mortality 
especially in patients with chronic non-communicable diseases 
(NCDs).
In view of the growing pressure on resources, health authorities 
need to continue learning from each other regarding potential 
additional measures they could consider to further improve the 
quality and efficiency of their prescribing. As a result, help achieve 
optimal pharmaceutical care [70]. The principal objective of this 
paper is to review a range of demand-side initiatives in ambulatory 
care across different countries and their resultant effects to provide 
future direction. We hope some of these initiatives will be particularly 
relevant to countries struggling to provide universal access in the face 
of growing prevalence of non-communicable diseases.
Methods
This is principally a narrative review of case histories based on 
publications or internal health authority documents known to the 
multiple co-authors. Alternatively, unpublished studies the authors 
have been involved with. This is not a systematic review of published 
papers as review papers appraising the many factors influencing 
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pharmaceutical expenditure, potential initiatives to improve 
pharmaceutical care as well as potential approaches to favourably 
influence physician prescribing, including enhancing the utilisation 
of generics, have already been published by the authors and others 
[34,57,70-77]. There have also been comprehensive publications to 
improve the quality and teaching of clinical pharmacology to enhance 
subsequent patient care [78].
We also did not critique the quality of any of the papers quoted in 
the case histories as a number of these involved the co-authors. 
However, we believe our approach is valid given the extensive 
and wide experience of the co-authors across countries as well as their 
publications on relevant subjects. This applied approach has been used 
in other publications aimed at providing guidance to health authorities 
including quality indicators for new medicines [4,26,34,49,73,77,79,80].
Results
The case histories across multiple countries (Figure 1) are collated 
as four different categories outlined in the introduction. This includes 
measures to enhance the prescribing of low cost generics versus 
originators or patented (single-sourced) products in a class, measures 
to improve adherence to prescribing guidance, measures to address 
concerns with adequate dosing and access to medicines as well as 
measures to improve adherence to medicines.
Measures to enhance prescribing efficiency through 
increasing use of generics
Prescribing efficiency in this situation refers to similar patient 
outcomes between different treatment approaches at lower expenditure. 
Encouraging the utilisation of generics versus originators: 
Scotland has introduced a range of measures and initiatives over the 
years to encourage INN prescribing. Activities start in medical school 
to educate students with the INN name of medicines, and continue 
into ambulatory care through education, monitoring and feedback as 
well as prescribing support systems [29,44]. This resulted in generics 
accounting for 98% to 99% of the total utilisation of medicines 
across a range of classes, enhanced by strict bioequivalence criteria, 
releasing considerable resources [29,44]. Health authorities have also 
successfully instigated pragmatic measures to enhance the prescribing 
of generics even when these are different salts to the originator with 
fewer indications, provided bioequivalence has been demonstrated. 
This was the case with generic clopidogrel when it became available 
[81].
Patient care is not compromised by such initiatives with published 
studies demonstrating similar outcomes between generics and 
originators to treat patients with cardiovascular diseases. This has even 
applied to medicines with narrow therapeutic indexes [82]. There were 
Figure 1: Countries involved in the case histories (red).
• Anti-epileptic drugs 
o Carbamazepine - it may be prudent to avoid changing the formulation particularly modified release preparations
o Phenytoin - there may be a pharmacokinetic basis for maintaining the same brand of phenytoin in some patients
o Phenobarbital, primidone - Commission on Human Medicines (CHM) advises physicians that patients should be maintained on the same brand*
• Asthma treatments 
o Theophylline modified release preparations – typically not seen as interchangeable with Council of the Royal Pharmaceutical Society advising that the brand name be 
specified on prescriptions
o Beclometasone dipropionate CFC-free inhalers as well as inhaler dry powder devices generally where administration approaches differ with different instructions 
impacting on patient familiarity 
• Calcium antagonists - modified release preparations, e,g. diltiazem longer acting and nifedipine modified release preparations, are typically seen as not interchangeable 
• Immunosuppressants - Cyclosporin – concerns with different bioavailability between different preparations
• Miscellaneous 
o Amphotericin intravenous - prescribe by brand name as doses depend on the formulation 
o Lithium – concerns with differences in bioavailability between different formulations
o Morphine sulphate slow release tablets – doses prescribed should be reviewed if the brand is change due to different release patterns between the different formulations
o Transdermal formulations of fentanyl - there may be important differences in formulations between the different brands leading to differences in release characteristics 
*CHM advice can be found at http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON336716
Box 1: Examples from the UK where there have been concerns with INN prescribing and the possible rationale based on recommendations in the British National Formulary 
(BNF), the Council of the Royal Pharmaceutical Society and the Medicines and Healthcare Products Regulatory Agency. (adapted from Ferner et al. [84] and Duerden et 
al. [85].
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similar findings for medicines to treat epilepsy [83], however, there are 
some concerns with INN prescribing of some of these medicines-Box 
1 [84,85]. 
It is believed INN prescribing should be encouraged as this can 
reduce confusion if patients are dispensed different branded generics 
with different names on different occasions. This can happen in 
Sweden with monthly auctions for multiple sourced products now 
taking place. The company winning the auction, through offering the 
lowest price and capacity to supply the Swedish market, is guaranteed 
an appreciable proportion of dispensed prescriptions for that 
particular molecule the following month [32,34,49]. This may cause 
confusion to patients if they are dispensed different branded generics 
on different occasions and do not receive adequate information 
about their medicines from dispensers [32,86], potentially leading 
to either duplication of medicines; alternatively, patients not taking 
their prescribed treatments as directed. As a result, not gaining the 
most benefit from their prescribed treatment [87]. These scenarios are 
exacerbated if dispensers lack training on how to handle concerns with 
substitution and/ or do not receive adequate payment for providing 
relevant information to patients, potentially limiting their time with 
them [45,86]. INN prescribing, apart from a limited number of well-
known situations (Box 1), is one way to address this as demonstrated 
in the UK [44]. 
However, such initiatives need to be carefully thought through 
before instigation to achieve the desired outcomes as illustrated by 
the experiences seen in the Health Authority of Abu Dhabi (HAAD). 
HAAD recently mandated INN prescribing apart from a limited 
number of exceptions similar to Box 1 [30,34]. This initiative combined 
with a comprehensive Generic Drug Policy (August 2009) sought to 
increase generic utilisation. However:
•	 Pharmacists	were	fully	reimbursed	for	dispensing	any	molecule	
and received bonuses from manufacturers to preferentially 
dispense their product (originator or branded generic)
•	 Originator	manufacturers	 did	 not	 have	 to	 lower	 their	 prices	
for reimbursement following generic availability, and patients 
did not have to pay the price difference for a more expensive 
molecule than the current lowest priced molecule
•	 Currently	 limited	 demand-side	 measures	 encouraging	
physicians to preferentially prescribe a generic versus a patented 
(single-sourced) product, e.g. a generic versus a patented PPI
As a result among the PPIs and statins, which were the two highest 
expenditure classes, utilisation of patented products grew following 
these various measures increasing overall costs [30]. HAAD is now 
considering a number of additional measures to address the situation, 
providing guidance to other countries of the need to fully think through 
potential future measures and initiatives before instigation.
Encouraging the utilisation of generics versus patented products 
in a class 
PPIs and statins: Multiple demand-side measures in the 
Netherlands encouraging the prescribing of generics, coupled with 
low prices of generic PPIs and statins at 2% of originator pre-patent 
loss prices, resulted in reimbursed expenditure for the PPIs and statins 
falling by 58% and 14% respectively in 2010 Vs. 2000 despite a 3 and 3.8 
fold increase in respective utilisation [36]. 
In Scotland, multiple demand-side measures coupled with low 
prices for generic PPIs and statins at 3% to 9% of pre-patent loss prices, 
resulted in reimbursed expenditure for the PPIs in 2010 56% below 
2001 levels despite a 3 fold increase in utilisation. Expenditure on the 
PPIs was estimated to be GB£159million (€200million) greater in 2010 
for a 5.2 million population without such measures [27]. Similarly, 
reimbursed expenditure for the statins in 2010 was only 7% above 
2001 levels despite a 6.2 fold increase in utilisation [27]. Again, it was 
estimated that statin expenditure would have been GB£290million 
(€364 million) greater in 2010 without such measures. 
Multiple demand-side measures in Sweden encouraging the 
prescribing of low cost generics at between 4% to 10% of pre-patent 
loss prices [32] resulted in expenditure/1000 inhabitants/ year in 2007 
for both the PPIs and statins at less than one tenth of that seen in the 
Republic of Ireland with their limited demand-side measures [46]. 
There was though greater morbidity among the selected population in 
Ireland [46]. Others have suggested different findings with increased 
prescribing of patented (single-sourced) products following the 
availability of generics [88]. However, the author aggregated countries 
with both extensive and limited demand-side measures, which may 
have impacted on the findings [88]. 
Patient care is not compromised with all PPIs and statins seen 
as essentially therapeutically similar at appropriate doses and there 
have been examples of successful therapeutic switching programmes 
between the statins [28,37,38,40,43,89].
Renin-angiotensin inhibitor drugs
ACEIs Vs. ARBs: Multiple demand side measures introduced 
in Scotland including guidelines, rigorous Drug and Therapeutic 
Committees (DTCs), academic detailing, benchmarking, prescribing 
targets and financial incentives, limited the prescribing of patented 
(single-sourced) ARBs versus generic ACEIs. As a result, the utilisation 
of ARBs was only 19% of total renin-angiotensin inhibitors in 2007 
(DDD basis). This compared with Portugal with few demand-
side measures to combat the marketing activities of patented ARB 
manufacturers. ARBs subsequently accounted for 44% of total renin-
angiotensin inhibitors in Portugal in 2007 [29]. The combination of 
multiple demand-side measures in Scotland coupled with low cost 
generic ACEIs, e.g. generic enalapril and lisinopril were 88% below 
pre-patent loss prices in Scotland in 2007, stabilised reimbursed 
expenditure on renin-angiotensin inhibitor drugs between 2001 and 
2007. This was despite a 159% increase in prescribed volumes. This 
compared with Portugal where reimbursed expenditure grew steadily, 
41% higher in 2007 than 2001, with volumes only increasing by 72% 
[29].
Patient care is not compromised with ACEIs and ARBs seen as 
having similar effectiveness at appropriate doses, prospective clinical 
studies showing coughing only occurred in approximately 10% of 
patients prescribed ACEIs and only 2% to 3% of patients in ACEI 
clinical trials discontinued their treatment due to coughing [29] 
Generic Vs. patented ARBs: A recent Cochrane review concluded 
all ARBs had a statistically equivalent effect on lowering blood pressure, 
which was endorsed by the National Institute for Health and Care 
Excellence (NICE) in the UK stating that patients with hypertension can 
be started on either an ACEI or a low cost ARB [41,90-92]. Alongside 
this, there had been no head to head trials showing any difference in 
effectiveness between the various ARBs to treat patients with heart 
failure, although higher doses are typically needed to manage heart 
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failure compared with hypertension [45]. In addition, a recent cohort 
study demonstrated that in patients with heart failure, higher doses of 
losartan (100 mg/ day) were not associated with increased mortality 
compared with candesartan, which is different for lower doses [93]. 
Lastly, there was perceived to be no detrimental effect on compliance 
with switching patients between different ARBs as all were prescribed 
once a day and there were no apparent issues with possibly different 
excipients between different generic losartan preparations [45]. As 
a result, care should not be compromised through encouraging the 
preferential prescribing of generic versus patented (single-sourced) 
ARBs at appropriate doses [41].
Multiple measures were successfully introduced in Sweden 
as well as one English primary care trust (NHS Bury) to improve 
ARB prescribing efficiency once generic losartan became available. 
Following the availability of generic losartan, the counties (regions) in 
Sweden instigated a number of measures to increase its prescribing. 
The various initiatives both nationally and regionally, collated under 
the 4Es – Education, Engineering, Economics and Enforcement [94], 
are described in Box 2.
These multiple demand-side measures (Box 2) significantly 
increased the prescribing of losartan following generics (Table 1) 
[92]. These initiatives, when combined with reduced prices for generic 
losartan at 10% of pre-patent loss prices, reduced total single ARB 
expenditure by 26% by the end of the study in Sweden despite a 16% 
increase in utilisation [92].
There were initially no specific demand-side measures in one 
primary care group in England (NHS Bury) to preferentially enhance 
the prescribing of generic losartan versus patented (single-sourced) 
ARBs once generic losartan became available [45]. However, this 
changed in March 2011 with the urgent need for this primary care 
group to save considerable resources in view of the current financial 
deficit. This led to a range of measures being instigated to enhance the 
prescribing of losartan in patients with hypertension versus patented 
ARBs. These have again been broken down by the 4Es [94]. Similar to 
Sweden (Box 2), these centred on therapeutic switching programmes 
(Box 3). These measures resulted in a significant increase in the 
prescribing of generic losartan (Table 2) [45]. 
• Education, e.g. support for professional initiatives including continuous medical education, distribution of printed guidelines and guidance including the ‘Wise List’ in 
Stockholm (below); academic detailing and the monitoring of prescribing against agreed guidance
o Changes in guidance, guidelines, and formularies to recommend losartan first line for the management of hypertension or heart failure when an ARB is indicated
o Academic detailing endorsing losartan as the ARB of choice
o Monitoring/ benchmarking the prescribing habits of physicians against colleagues and against agreed guidance on a monthly basis and feeding the results back to 
preferentially encourage the prescribing of losartan
• Engineering, e.g. organizational or managerial intervention, including prescribing and quality targets
o Prescribing targets, e.g. % losartan as a % of all ARBs (DDD based)
o Active therapeutic switching programmes among some counties to switch patients on other ARBs to losartan
• Economics, e.g. financial incentives to physicians and patients including devolved budgets to physicians combined with financial incentives and additional co-payments 
for a more expensive drug than the current reimbursed drug (molecule or class) 
o Devolution of budgets to physicians combined with financial rewards for staying within budget
o Revision of physician or practice based financial incentives to now include the prescribing of losartan versus other ARBs
• Enforcement, e.g. regulations including those enforced by law such as compulsory generic substitution and prescribing restrictions
o There were no national prescribing restrictions for patented ARBs versus generic losartan
o However, the restrictions limiting the prescribing of ARBs to second line still remained in place
Box 2: Multiple measures to enhance the prescribing of losartan in Sweden once generics became available collated under the 4Es [32,50,92,94-96].
Months -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 10 12 14 16
% Losartan 26 26 26 27 27 27 27 27 27 30 30 33 34 35 38 38 40
% other ARBs 74 74 74 73 73 73 73 73 73 70 70 67 66 65 62 62 60
Table 1: % losartan and other ARBs vs. total ARBs (DDD basis) in the months pre- and post generic losartan (Month 0) in Sweden (Month 0 – March 2010) [92].
Education 
• Educating physicians that all ARBs are similarly clinically effective as part of a programme of meetings between the Medicines Management Team and all GP practices 
before any patient switching to introduce the prescribing incentive scheme, explain the programme, gain agreement and deal with any clinical issues that may arise
• Continued educational input to ensure continued high INN prescribing of losartan
• GPs subsequently informed patients why the switch had taken place to reduce potential confusion. Relevant community pharmacists were also informed about the 
campaign to enlist their help with reassuring patients at the time of dispensing to address any additional concerns and reduce possible patient confusion if this was 
required
Engineering
• Generic losartan included in prescribing targets for ARBs - target was that 85% of all renin-angiotensin inhibitor drug items prescribed were either an ACEI or losartan 
• Instigation of therapeutic switching programmes for patients with hypertension currently prescribed other ARBs than losartan. This was undertaken by pharmacists and 
pharmacy technicians under Standard Operating Procedures (SOPs) agreed by the NHS Bury Medicines Management sub-group 
• Under the SOPs, Medicine Management technicians undertook searches of GP clinical systems to identify potential candidates for therapeutic switching. GPs agreed 
to substitute losartan at their next prescription.
• Where potential concerns were identified in patients’ medical histories, these were first discussed with medication review pharmacists in the Medicines Management 
group before any subsequent decision was taken 
• All decisions to change were the ultimate responsibility of each GP. They were given a list of patients identified for potential switching by the technicians. They 
subsequently signed the list if approved; alternatively removed the patient from the list if concerns. Patients were recalled after 2 to 3 months and switched back to their 
original ARB if their BP was not controlled. Subsequently monitored regularly as part of the Quality and Outcome Framework initiative
Economics
• Devolved drug budgets taking account of generic losartan
• 15% of prescribing incentive monies (overall up to GB£0.90/ patient) to GP practices for meeting their prescribing targets for ACEIs and generic losartan
• 20% of the prescribing incentive scheme allocated to practices for coming within their indicative prescribing amount (generic losartan would contribute to this)
Enforcement
• Not applicable
Box 3: Multiple demand-side activities undertaken in NHS Bury to enhance the prescribing of generic losartan broken down by the 4Es (Adapted from reference [45].
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As seen in Table 2, there was no immediate change in the utilisation 
of losartan in NHS Bury following the availability of generics. This 
changed after multiple demand-side measures were instigated (Box 
3) principally involving the medicines management team. Following 
these multiple measures, losartan utilisation increased significantly to 
65% of all single ARB items dispensed by the end of the study Table 
2 [45]. Reimbursed expenditure on total single ARBs was 59% below 
pre-generic levels (M0) by the study end, helped by a 92% reduction in 
expenditure/ item for losartan. Annual net savings from the programme 
were estimated at just under GB£290,000 (€365,000), over eight times 
the cost of implementation [45].
Patient care was not compromised with patients actively followed 
up by physicians. Similar findings have been seen with other therapeutic 
switching programmes for ARBs in the UK [40,41].
Atypical antipsychotics: It is recognised by psychiatrists, clinical 
pharmacologists, pharmacotherapeutic experts and health authorities 
that there are classes where it can be difficult to introduce demand-side 
measures to appreciably increase the prescribing of multiple sourced 
versus patented medicines in a class. This is seen with the atypical 
antipsychotics for treating schizophrenia and bipolar disease. Experts 
as well as national authorities suggest pharmacotherapeutic treatment 
should be tailored to individual patients in view of the differences in 
effectiveness and side-effects between individual patients [8,97].
A recent cross national study showed there was a consistent 
decrease in risperidone utilisation as a percentage of all selected atypical 
antipsychotics following the availability of oral generic risperidone 
among a number of European countries, with no specific demand-side 
measures to preferentially encourage the prescribing of risperidone [8]. 
There were similar findings in Austria and Spain (Catalonia) [8,97]. 
Consequently, health authorities need to wait until more atypical 
antipsychotic drugs become available as generics before they will see 
significant reductions in expenditure. This is already happening across 
Europe [8] .
Guidelines/ prescribing guidance by physician directed DTCs 
and other bodies
‘Wise List’ – Stockholm Healthcare Region
 In Stockholm Metropolitan Healthcare Region, with a population 
of 2 million people, there has been a tradition to select evidence-based 
medicines recommendations for common diseases during the past 
five decades directed by a high degree of involvement of prescribing 
physicians and respected pharmacotherapeutic experts and clinical 
pharmacologists [32]. The long term strategy has been to advocate that 
“each recommended medicine should be of high value to the patient” 
[50,51].
Since 2000, approximately 200 medicines have been selected for 
common diseases seen in ambulatory care including primary and 
outpatient care [50]. The recommended medicines are selected based 
on strict criteria including efficacy, safety and cost-effectiveness 
(Box 4), with each recommended medicine typically available for a 
minimum of two years on the Swedish market before consideration. 
Key questions are also asked when new medicines are being considered 
for potential inclusion in the formulary (Box 4). Since 2000, the list 
has been called the ‘Wise List’ with several different editions available 
including one for patients and one for the public. The ‘Wise List’ is 
updated yearly [50].
Respected specialists, working jointly with clinical pharmacologists, 
pharmacists and general practitioners in over 20 expert groups, suggest 
which medicines should be selected and included in the list [32,50]. The 
suggestions are approved by the DTC, with all approved suggestions 
subsequently collated into the ‘Wise List’ for that year, and widely 
communicated and disseminated [50,51].
Adherence to the voluntary ‘Wise List’ has increased during the 
past 10 years, enhanced by physician trust in the List, reaching 87% 
of all prescriptions in primary care in 2009 [50]. An essential step to 
assure high adherence has been to provide all prescribers with easy-to-
use tools to compare their prescribing and adherence with each other, 
Month -5 -3 -1 0 1 3 5 7 M0 M1 M3 M5 M7
Losartan 1107 1206 1237 1288 1188 1229 1343 1181 1399 1307 1894 2805 3201
All other ARBs 3484 3867 3835 4021 3634 3610 3974 3376 3873 3403 3556 2430 1752
% losartan 24 24 24 24 25 25 25 26 27 28 35 54 65
Table 2: Utilisation of losartan versus other ARBs (DDD basis) in items dispensed and percentages in NHS Bury before and after generic losartan [45]
NB. Months (numerical) = before and after generic losartan in July 2010 (-5 to 7). M0 to M7 = months after the initiation of multiple measures (Box 3) to increase losartan 
utilisation. % losartan = % losartan items dispensed vs. all ARB items dispensed in that month.
A) Key Criteria for listing
•	 Efficacy and safety – based on available evidence preferably including data from RCTs 
•	 Pharmaceutical suitability – formulations, strengths, and pharmacokinetic properties
•	 Efficiency – mainly based on comparative reimbursed prices and the overall drug budget impact 
•	 Experience – mainly concerned with drug safety
•	 Environmental aspects – if drugs are considered similar based on available evidence and similarly priced, environmental considerations guide choices
B) Key questions posed when considering new medicines for potential listing
1. What was the main scientific question posed? 
2. How was patient selection conducted and diagnoses, etc.?
3. What patients were included in the control groups and what type of study was conducted?
4. Was the study-double-blinded, single-blinded, etc.?
5. How was the randomisation conducted?
6. What about the pharmacokinetics? 
7. What about concomitant medications, are these documented, valid, etc.?
8. Are the drug effects well defined, relevant, reproducible, etc.?
9. What about adverse events, are these well studied, described, etc.?
10. How appropriate was the statistical design and evaluation of the results?
11. What about the conclusions of the studies – were these adequate, doubtful, etc.?
Box 4: Key criteria and questions typically posed in Stockholm Metropolitan Health Care Region when reviewing existing and new medicines for inclusion in the ‘Wise List’ 
[32].
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and between different healthcare settings, as well as provide prescribing 
guidance in an easy-to-use format [32,50]. This is seen as critical to the 
successful utilisation of the ‘Wise List’ in prescribing activities.
Separate studies have demonstrated that care is not compromised 
with adherence to the ‘Wise List’ recommendations, which typically 
include generic versus patented medicines in a class [98]. Overall, an 
annual increase in adherence by 1% in primary care in Stockholm is 
equivalent to €0.47 lower cost/prescription item [96]. This corresponds 
to annual additional savings in primary care in Stockholm healthcare 
region of €4 million or more, with the savings accelerating over time. 
This is in addition to improving patient care through physicians 
increasing their prescribing of medicines with proven outcomes as 
opposed to new medicines with as yet unknown long term benefits 
[12]. Adverse drug reactions and potential drug interactions are also 
reduced by the development and instigation of an alert system (SFINX) 
as part of the comprehensive approach decision support system for 
physicians within Stockholm healthcare region [99,100]. SFINX is also 
utilised throughout Sweden and other countries, e.g. Finland [99].
Guidelines for Alzheimer’s disease and their implementation
As mentioned, educational outreach visits (academic detailing) 
have been shown to improve prescribing practices of healthcare 
professionals including the incorporation of clinical guidelines into 
clinical practice, although the results can be variable [57,58,101-103]. 
This activity has been incorporated into current demand-side 
measures in the State of Minas Gerais, Brazil. For certain medicines to 
be reimbursed in Minas Gerais, which include high cost and speciality 
medicines, physicians must follow agreed prescribing guidelines. 
Patients must pay 100% of the cost of the medicines if physicians do 
not meet the agreed prescribing criteria; alternatively physicians fail to 
complete the forms correctly. Educational activities are subsequently 
undertaken where pertinent to help improve physician adherence to 
agreed guidelines and reduce the potential for patient co-payments. 
The state of Minas Gerais believes this approach encourages the 
appropriate prescribing of medicines to patient groups where they 
provide the greatest benefit and value. 
Recently, guidelines have been developed to improve the 
management of patients with Alzheimer’s Disease in Minas Gerais. This 
is because dementia disorders are seen as the most common disease 
among the elderly in Brazil, reducing their social and occupational 
activities. Specific forms were designed for physicians to request 
Figure 2: Example of educational handouts in Minas Gerais as part of the academic detailing programme (Reproduced with kind permission of the State of Minas 
Gerais)
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funding for the cholinesterase inhibitors, i.e. donezepil, galantamine or 
rivastigmine, based on the agreed guideline of care. 
An analysis undertaken in 2012 showed that 12% of the treatment 
requests for Alzheimer’s disease were returned or denied due to a lack 
of knowledge about the guidelines (Personal communication Guerra 
Junior AA). Consequently, activities have been ongoing to address 
this to improve the care of these patients. This includes academic 
detailing based on the clinical protocols and treatment guidelines for 
Alzheimer’s Disease. This involves a six-step process including:
•	 Step	 1 - Information survey among physicians concerning 
their knowledge of the disease. Subsequently, a seminar about 
the disease with key facts
•	 Step	2 - Study of clinical cases from both accepted and denied 
requests to gain practical knowledge
•	 Step	 3 - Elaboration of two educational handouts for the 
academic detailing programme: one focused on patients and 
caregivers, and the other focused on physicians or other health 
professionals with the principal aim of assisting the physicians 
in adequately completing their requests (Figure 2)
•	 Step	4 - Training of pharmacy personnel for the educational 
outreach visits in a workshop
•	 Step	5 - Academic detailing to orient prescribers. In addition, 
completing a report of the visit containing the prescriber`s 
impression of the process and their level of satisfaction
•	 Step	6 - Evaluation of the study and the impact on improving 
guideline adherence
The study is still ongoing. If successful, this approach will be 
applied to other situations to efficiently improve the quality of care in 
Minas Gerais. 
Antibiotic prescribing and dispensing in Serbia
There has been high antibiotic consumption in Serbia, with 
antibiotic consumption enhanced by self-purchasing in pharmacies. 
This self-purchasing increased antibiotic utilisation by 115% to 
128% in recent years compared with reimbursed utilisation (via The 
Republic of Serbia Health Insurance Fund database). This resulted in 
Serbia having the third highest utilization for cephalosporins in 2007 
among European countries, highest for penicillins, second highest for 
macrolides, and third highest for quinolones [104]. Consequently, 
reducing antibiotic consumption became a high priority among all 
national authorities to reduce resistance development and conserve 
resources. This is happening with greater enforcement of the law 
regarding self-purchasing following information and other campaigns, 
as well as the instigation of prescribing restrictions for second line 
antibiotics [104].
Concerns with the quality of prescribing 
We are aware that there are countries where there are currently few 
activities among national or regional health authorities or professional 
medical groups to improve the quality and efficiency of prescribing in 
ambulatory care. The principal means of controlling pharmaceutical 
expenditure in a number of these countries has been through patient 
co-payments and reference pricing in a class (ATC Levels 3 to 5). 
This can potentially affect the resultant quality of care especially if 
prescribing choices are affected by co-payment issues [105-107]. 
Care can also potentially be affected if there is limited or no 
continuing physician professional development programmes to 
improve patient care through for instance improving aspects such as 
diagnosis and the dosing of medicines as well as knowledge of adverse 
drug reactions and drug interactions. The various initiatives in the 
Stockholm healthcare region surrounding DTCs and the ‘Wise List’, 
described earlier, is one way to help address this alongside for instance 
the development of quality indicators including those to improve 
pharmaceutical care [50,51,70,79,99]. However, care when introducing 
quality indicators in case of potential overload as well as unintended 
consequences [79].
Regulating pharmaceutical company marketing activities could 
also help improve the quality of prescribing, especially given some 
of the aggressive marketing and other activities that have taken place 
to influence physician prescribing [12,108-110]. The authorities in 
Croatia recently introduced strict controls regarding pharmaceutical 
company marketing activities. These included limiting contact 
between company representatives and physicians, as well as reporting 
all promotional expenses including any financial remuneration to 
physicians to the authorities to limit such activities [111]. Adherence is 
enhanced through a yearly financial deposit with Croatian Institute for 
Health Insurance (CHIF) with penalties for abuse, alongside potential 
delisting of products from the public reimbursement list and ‘naming 
and shaming’ offenders in public [111]. There have been similar 
activities in other countries [110].
We are also seeing health authorities working with physicians and 
other stakeholder groups pre-launch to improve the prescribing of new 
medicines post launch if there are concerns with patient safety when 
the new medicine is prescribed in a wider co-morbid population in 
routine clinical care. This happened with the recent introduction of 
dabigatran to prevent stroke and systemic embolism/clot formation in 
adult patients with non-valvular atrial fibrillation [12]. These concerns 
arose due to dabigatran’s low mean oral bioavailability, considerable 
variation in plasma drug concentrations, and dependence on renal 
elimination of the active metabolite. Consequently, any accumulation 
of dabigatran in patients with reduced renal function will increase their 
risk of excessive bleeding, complicated by no known antidote and no 
commercially available assay to measure blood levels of dabigatran 
[12,17,112,113]. These concerns are enhanced by potentially more 
elderly patients in clinical practice than seen in the Phase III clinical 
studies increasing the risk of bleeding, which happened post-launch 
[12,113,114]. These concerns resulted in European health authorities 
and those in other countries instigating education and other activities 
in an attempt to improve the prescribing of dabigatran post-launch 
[9,12]. In New Zealand, extensive local educational initiatives by the 
Best Practice Advisory Centre (BPAC) in the Lower Hutt region as 
well as initiatives by local prescribers pre- and peri-launch resulted 
in no inappropriate prescribing of dabigatran according to patients’ 
renal function post-launch [9]. Prescribing restrictions for dabigatran 
post-launch in Slovenia, e.g. only reimbursed if initiated by an internist 
or neurologist and prescribed according to agreed indications with 
patients entered onto databases and followed in a tertiary or secondary 
anticoagulation centre, also appeared to have enhanced the quality of 
prescribing post-launch [9] .
Adequate dosing of medicines and access to medicines
There appear to be under dosing of statins among a number of 
countries including Ireland, Netherlands, Norway, South Africa and 
the Stockholm healthcare region. An analysis of a cohort of patients 
aged ≥18 years in the Finnish Prescription Registry Finland prescribed 
statins for the first time showed that patients were typically initiated 
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with simvastatin (94% of the cohort) as 10 or 20 mg tablets. In addition, 
a considerable proportion of patients initiated on statin therapy 
with less potent doses remained at the initial dose after 1 year. This 
suggested potential under dosing was common, even among patients 
with a high CV risk [39]. The average dose of simvastatin for secondary 
prevention patients in Ireland was 22 mg in a recent study [32,115]. 
This was 20.4 mg in Stockholm with an appreciable proportion of 
patients dispensed only 10 mg of simvastatin[27,32]. There also 
appeared to be under dosing with simvastatin in the Netherlands with 
many patients prescribed starting doses at just over 15 mg (mean dose 
of 1.02 +/- 0.39 defined daily doses with the DDD for simvastatin at 15 
mg during the study) [116].There was also variable dosing of statins 
among the different regions in Norway with under dosing in some 
regions. Patients in high statin consumption regions in Norway had 
the highest prescribed daily dose for simvastatin across all patients at 
25.9 mg; similarly for atorvastatin at 21.9 mg. In addition, more users 
received tablets in the upper range of available strengths than seen in 
the low consuming regions in Norway [117]. 
In South Africa, a recent retrospective, cross-sectional 
pharmacoepidemiological study was conducted on claims data for 
2011 of a medical insurance (medical aid) administrator provider. This 
included 4,805 patients (57% males) prescribed 38,373 hypolipidaemic 
agents, with all records extracted for analysis. Each medication record 
contained information on the age and gender of the patient, with a 
unique number to identify each patient, the date of the prescription as 
well as detailed information on the dispensed drug (name, package size, 
formulation, strength and quantity). Statin doses varied considerably, 
with the average prescribed daily dose of simvastatin for both men and 
women in 2011 at 23.7 mg, higher for atorvastatin averaging 20.9 mg 
[118] (Table 3).
This compares with substantial prescribing and dispensing of 
higher strength simvastatin (principally 40 mg simvastatin) and 
atorvastatin in England and Scotland following physician incentives 
under the Quality and Outcome Framework (QoF) [27,28,44].This 
was part of the initiative in the UK to improve the standard of care in 
patients treated in ambulatory care facilities [68]. As part of the QoF 
initiative, physicians received substantial payments for achieving lipid 
level targets in their patients with hypercholesterolemia [27,28,68]. 
This combined with national guidelines in Scotland advocating 40 mg 
simvastatin for secondary prevention including patients with diabetes 
[119,120] appreciably enhanced the prescribing of 40 mg (principally) 
and 80 mg (limited) simvastatin versus 10 and 20 mgs in recent years 
(Table 4).
There are though European countries where there has been 
limited utilisation of statins even without considerations of the doses 
prescribed [77]. This included Lithuania where in 2007 statin utilisation 
was just 0.8 DIDs (DDDs/ 1000 inhabitants per year - DIDs) compared 
with 93.6 in England and 114.74 in Scotland [77]. This difference can 
be explained by the considerable prescribing restrictions for statins 
in Lithuania at that time, i.e. statins were only reimbursed post AMI 
and only for 6 months otherwise 100% co-payment. In addition, the 
first prescription must be written by a cardiologist [77]. This compares 
with the encouragement in England and Scotland through the QoF 
targets, and statins fully reimbursed across all populations [27,28]. The 
restrictions have now eased in Lithuania. This resulted in the utilisation 
of statins increasing to 7.3 DIDs in 2012, higher at 12.9DIDs if patients 
paying 100% co-payment are included. 
This is considerably different to the situation with renin-
angiotensin inhibitor drugs in Lithuania. These are fully reimbursed 
in Lithuania without prescribing restrictions, which led to similar 
utilisation patterns in 2007 compared with other European countries 
(Table 5) [29,121].
Reducing the prevalence of non-communicable diseases (NCDs) 
is seen as a priority area across all countries given rising prevalence 
rates in recent years [122,123] This has resulted in the instigation of 
broad policy measures and communication programmes in Pakistan, 
including encouraging behavioural changes such as diet and exercise as 
well as screening for raised BP, dyslipidaemia and diabetes in high-risk 
groups. However, initial analysis suggests marked differences in the 
standard of care whether patients are treated in private versus public 
facilities. This included the extent of examinations and tests undertaken. 
Lipid lowering drugs including statins were the most prescribed drugs 
at 24% of all prescriptions. The majority of prescriptions though 
emanated from private physicians, with only a limited number from 
public providers. This was not helped by lipid lowering drugs typically 
being unavailable in most public health care facilities [122]. This 
situation needs to be urgently addressed to help reduce the morbidity 
and mortality of patients with diabetes across all sectors in Pakistan. 
Improving adherence to medicines especially for chronic 
diseases
The next challenge facing health authorities is to enhance 
medication adherence. This is particularly a challenge in patients 
with chronic asymptomatic NCDs as demonstrated in a number of 
publications [63-65,124].
A survey on hypertensive patients in seven primary health clinics in 
Malaysia found that 46.6% of the patients were non-adherent to their 
medication regimes [125]. A similar study in diabetic patients found 
that 53% of the patients surveyed were non-adherers [69]. In both 
studies, several factors appeared to affect medication adherence. These 
included patients’ genders, age and race as well as their medication 
knowledge, the total number of drugs prescribed, dosing frequencies 
and the level of co-morbidities. In a third study involving different 
healthcare professionals, non-adherence was top of the list of identified 







Table 3: Prescribed Daily Dose (PDD) in mgs for patients in South Africa dispensed 
statins in 2011 [118].
Activity HP Study QoF
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
10 + 20mg 23.88 28.18 33.74 36.92 39.91 42.77 44.75 45.39 44.01 41.52 39.09
40 + 80mg 1.49 2.83 6.08 12.99 26.26 40.43 52.68 68.52 81.25 91.21 98.31
NB: HP = Heart Protection study and QoF=Quality and Outcomes Framework
Table 4: Dispensing of different tablet strengths of simvastatin (millions of tablets) among National Health Service patients in Scotland 2000 – 2010 (adapted from [27]).
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medicine issues followed by incorrect administration of medicines 
[126]. This study also demonstrated the importance of pharmacists 
working in collaboration with other healthcare professionals, especially 
physicians, to identify and resolve pharmaceutical care issues to 
provide optimal care [126].
There have been a number of activities initiated by the Ministry 
of Health in Malaysia (MOH) to improve medication adherence in 
patients with diabetes. This includes producing information booklets as 
well as initiating medication adherence clinics [127]. These medication 
adherence clinics, or Medication Therapy Adherence Clinics (MTACs), 
are clinics manned by trained pharmacists located in the physician’s 
clinic for 12 disease states including diabetes. The protocol for DMTAC 
(Diabetes MTACs) requires selected patients to attend the clinic at least 
once every three months for two years. These are typically problematic 
cases failing at routine care settings. As a result, they receive more 
intensive and personalised follow-up than seen during normal clinics. 
DMTAC patients have uncontrolled diabetes with HbA1c >8.0%, 
fasting blood glucose (FBS) > 6.1 mmol/l or 2 hours post prandial 
sugar level >8.0 mmol/l. They typically have co-morbidities including 
macrovascular and microvascular complications and are prescribed 
multiple medications. The objective of DMTAC clinics is to enhance 
the adherence to the medications prescribed as well as monitor any 
untoward side-effects. As previously discussed, good control of blood 
pressure and adequate dosing of statins can help reduce morbidity and 
mortality in these patients. Since its inception in 2004, up to 2013, there 
are 378 DMTACs with 10,532 patients attending such clinics either in 
hospitals or health clinics across Malaysia.
Cross-sectional studies have recently been performed to assess 
differences in subsequent adherence rates between patients attending 
DMTACs and a control group within government facilities. Facilities 
were categorized as National Referral Hospitals, State Hospitals, 
Hospitals with Specialists, Hospitals without Specialists and Health 
Clinics. A total of 2486 patients were included in the study through 
a systematic random selection process. The impact of DMTACs on 
education and adherence was assessed using the Morisky Medication 
Adherence Scale (MMAS-4) tool [128]. Odds-ratio analysis of 
non-adherence showed that race, household income and age were 
significant indicators for poor adherence. However, there appeared to 
be no significant difference in adherence rates between the two groups. 
There was also no corresponding significant increase in HbA1c control 
in the DMTAC versus control groups.
These findings may be in part due to differences in sample sizes 
and patient characteristics between the two groups, especially given the 
characteristics of patients referred to the DMTACs. They may also be 
due to the fact that patients were only seen once every three months, 
e.g. Rothman and colleagues in the US studied a total of 217 Type 2 
DM patients with poor glycaemic control who received an intensive 
diabetes management from clinical pharmacists every 2 to 4 weeks for 
a period of 12 months. They did show a significant HbA1c reduction 
of 2.5% [129].
These findings and their implications are now being analysed 
since continuous medication counselling and monitoring the disease 
status of patients is seen as an essential component to reduce future 
morbidity and mortality in patients with diabetes. This could include 
agreed HbA1c goals for DMTAC patients as well as potentially greater 
intensity in the number and extent of patient visits, especially initially, 
with a number of studies showing a positive effect of such activities on 
glycaemic control [129-132].
This study also reviewed the impact of non-adherence on the 
accessibility and availability of medicines at the various health facilities. 
This is relevant since budgetary constraints can limit formulary listings 
and subsequently impact on medication use. The results showed that 
most of the essential anti-diabetic drugs (ADA) are listed at all health 
facilities and are being prescribed to patients. However, there were large 
differences in the cost of medications per patient between facilities, 
which was mainly due to differences in prescribed medications for 
patient co-morbidities. This study showed medication accessibility and 
availability for ADAs was not the main issue, which is important when 
looking to appropriately managing patients with diabetes and any 
associated co-morbid diseases to improve their outcomes.
Discussion
A number of inferences and conclusions can be drawn from 
the various case histories outlined in the four sub-sections. Firstly, 
regarding potential initiatives to enhance the prescribing of generics 
versus originators, the findings in Scotland provide an example of a 
long-term approach to enhance INN prescribing. As a result, reduce 
potential patient confusion if different branded generics are dispensed 
on different occasions. This is especially important if dispensers lack 
training on how to handle concerns with substitution and/ or do 
not receive adequate payment for providing relevant information to 
patients potentially limiting their time with them [45,86].  However, 
the example of HAAD shows that authorities must fully think through 
any measures else there could be disappointment with the outcomes 
[30].
The findings also suggest that both supply-side measures lowering 
the prices of generics to 2% to 10% of pre-patent loss prices, coupled 
with multiple demand-side reforms, can appreciably enhance 
prescribing efficiency for pertinent classes once generics become 
available in the class. They also demonstrate that the influence of 
demand-side measures appears to be additive as illustrated by greater 
prescribing efficiency for the PPIs in the Netherlands, Sweden and 
the UK (Scotland) with their multiple and intensive demand-side 
measures compared with the Republic of Ireland with fewer measures 
[27,36,46]. As mentioned, this resulted in expenditure in Ireland being 
over ten times that seen in Sweden when adjusted for population size 
for both the PPIs and statins, although the population in Ireland had 
greater co-morbidity [46]. A similar situation is seen with limiting the 
prescribing of ARBs versus generic ACEIs in Scotland compared with 
Portugal with its fewer demand-side measures [29] 
No change initially in the utilisation of losartan post generics in 
NHS Bury, even though there had been initiatives generally among 
primary care groups in the UK to enhance the preferential prescribing 
of generics including generic ACEIs versus patented ARBs [29,44,45], 
was also seen in other European countries and regions. These included 
Ireland, Scotland and Spain (Catalonia). In each country there were 
also no specific activities encouraging the preferential prescribing of 
losartan [44,45,133]. This suggests that there is no spill over of learnings 
from one class to another to favourably affect physician prescribing 
habits. Consequently, multiple measures are needed to effect changes 
in prescribing habits. This mirrors the findings from other studies 
[44,134]. This finding may be mitigated to some extent on this occasion 
by the increased complexity in the message among health authorities, 
i.e. going from encouraging the prescribing of generic ACEIs first line 
versus patented ARBs to generic ACEIs and low cost ARBs first line 
versus patented ARBs [29,133,135].
The need to make considerable savings from the combination of 
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supply- and demand-side measures without compromising patient 
care is becoming increasingly important given the continual pressure 
on resources coupled with the desire of authorities to either increase 
patient access to medicines; alternatively, continue to provide equitable 
and comprehensive healthcare. All healthcare professionals play a key 
role with helping to achieve this. This includes pharmacists working 
with medicine management teams at local, regional or national health 
authorities. The active involvement of physicians is also important 
to achieve desired results. However, it is recognised there are classes 
where it is difficult to introduce demand-side measures due to the 
need to tailor pharmacotherapy to the individual patient, e.g. atypical 
antipsychotics [8].
The ‘Wise List’ approach within the Stockholm Metropolitan 
Healthcare Region shows that comprehensive strategies can be 
undertaken over time to improve the rational use of medicines (RUM). 
This includes improving the interface between hospital and ambulatory 
care. This has become increasingly important with many new premium 
priced drugs, including new biological drugs, initiated in hospital 
[51]. High adherence rates have been achieved through instigating 
programmes to access knowledge at the point of care, involving 
respected therapeutic experts and physicians in the development 
process, continuous medical education of prescribers around the 
‘Wise List’ and the systematic approaches to the introduction of new 
medicines [50]. This pragmatic approach, linking prescribing guidance 
and advice for designated medicines – ‘Wise Advice’, also avoids 
guideline overload. Guideline overload was seen in France with their 
extensive number of guidelines for clinicians in ambulatory care, which 
eventually led to their demise [136,137]. As mentioned earlier, the same 
advice is given to health authorities when developing and instigating 
quality indicators [79].  The ‘Wise List’ has now been translated into 
Serbian to form part of the long term strategy of the Republic of Serbia’s 
Health Insurance Fund to improve the quality of care in ambulatory 
care. Other countries could learn from such initiatives, especially those 
where there are currently few health authority initiatives to improve 
physician prescribing and subsequent patient care. The situation in 
the State of Minas Gerais with initiatives to improve the prescribing of 
medicines for patients with Alzheimer’s Disease (Figure 2) will also be 
monitored to provide future guidance. 
It is likely that we will also see increased activities pre- to post-
launch for new medicines to optimise their use, especially where there 
are safety and/ or budgetary concerns. This builds on the situation with 
dabigatran [9,12].
The findings regarding the prescribed doses for statins make it 
essential for health authorities to monitor prescribed doses as more 
information becomes available. Otherwise, they may fail to achieve 
the desired result. The findings in South Africa suggest that potential 
under dosing may not be the same for all statins (Table 3), so targeted 
educational and other activities may be needed. The approach in the 
UK with multiple initiatives, including incentivising physicians to 
achieve lipid target levels, may be one way forward if pertinent (Table 
4). 
The findings initially in Lithuania as well as in Pakistan suggest it 
is also essential for health authorities to introduce policies to enhance 
patient access to low cost generic statins and other pertinent medications 
to reduce the morbidity and mortality associated with chronic NCDs. 
Otherwise, they may fail to reach their desired objectives. The findings 
in Lithuania regarding the appreciable difference in the utilisation of 
statins and renin-angiotensin inhibitor medicines (Table 5), as well as 
the considerable difference in statin utilisation between Lithuania and 
the UK, make it mandatory for authors to report associated policies 
when undertaking cross national utilisation studies else there could be 
concerns with the validity of the data [121].
Once these policies are in place, strategies should be aimed at 
enhancing adherence especially in patients with chronic asymptomatic 
diseases. The activities by the Ministry of Health in Malaysia to 
improve medication adherence in patients with chronic diseases 
[MTACs] including diabetes [DMTACs] also provides direction to 
other countries seeking to reduce morbidity and mortality associated 
with NCDs. However, the situation is complex with typically multiple 
strategies needed [63,64,124]. In addition, patient values should also be 
explored including their priorities, life philosophy and their background 
to improve future adherence rates [138]. The studies described also 
show it is imperative for the authorities to monitor the impact of their 
interventions in order to review and plan pertinent further activities if 
the desired results are not being achieved. Otherwise, they may fail to 
reach their desired outcomes.
In conclusion, a number of case histories demonstrating potential 
ways for all key stakeholder groups to enhance prescribing efficiency 
have been discussed to provide future guidance. These also include 
learnings from case histories where the desired results have not been 
achieved, and potential ways forward. We believe it is increasingly 
important for countries and regions to learn from each other in the 
face of growing resource pressures. Without such learnings, countries 
may well struggle to continue to increase patient access or continue to 
provide comprehensive and equitable healthcare.
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